-
Propofol vs etomidate for induction prior to invasive mechanical ventilation in patients with acute myocardial infarction Am. Heart J. (IF 4.8) Pub Date : 2024-03-28 Alexander Thomas MD, Soumya Banna MD, Andi Shahu MD MHS, Tariq Ali MD MBA, Christopher Schenck MD, Bhoumesh Patel MD, Andrew Notarianni MD, Melinda Phommalinh PA, Ajar Kochar MD MHS, Cory Heck PhD BCCP, Sean van Diepen MD MSc, P. Elliott Miller MD MHS
Patients with acute myocardial infarction (AMI) requiring invasive mechanical ventilation (IMV) have a high mortality. However, little is known regarding the impact of induction agents, used prior to IMV, on clinical outcomes in this population. We assessed for the association between induction agent and mortality in patients with AMI requiring IMV. We compared clinical outcomes between those receiving
-
Assessment of the CLOT (children's likelihood of thrombosis) real-time risk prediction model of hospital-associated venous thromboembolism in children with congenital heart disease Am. Heart J. (IF 4.8) Pub Date : 2024-03-21 Sudeep D. Sunthankar MD MSCI, Ryan P. Moore MS, Daniel W. Byrne MS, Henry J. Domenico MS, Allison P. Wheeler MD MSCI, Shannon C. Walker MD, Prince J. Kannankeril MD MSCI
-
Different Dose Aspirin Plus Immunoglobulin (DAPI) for Prevention of Coronary Artery Abnormalities in Kawasaki Disease: Study Protocol for a Multi-centre, Prospective, Randomized, Open-label, Blinded End-point, Non-inferiority Trial Am. Heart J. (IF 4.8) Pub Date : 2024-03-19 Yujian Wu MD, Lin Hu MM, Xiaofei Xie MM, Wei Li MD, Yanfei Wang PhD, Li Zhang MM, Ping Huang MD, Fengxiang Li MM, Jianbin Li MM, Shuliang Xia MM, Jia Yuan MM, Ming Li MM, Zhouping Wang MD, Xu Zhang MD
Kawasaki disease is a pediatric acute systemic vasculitis that specifically involves the coronary arteries. Timely initiation of immunoglobulin plus aspirin is necessary for diminishing the incidence of coronary artery abnormalities (CAAs). The optimal dose of aspirin, however, remains controversial. The trial aims to evaluate if low-dose aspirin is non-inferior to moderate-dose in reducing the risk
-
Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial) Am. Heart J. (IF 4.8) Pub Date : 2024-03-16 Pierre-Grégoire Guinot MD PhD, Olivier Desebbe MD PhD, Guillaume Besch MD PhD, Philippe Guerci MD PhD, Philippe Gaudard MD PhD, Diane Lena MD, Paul Michel Mertes MD PhD, Osama Abou-Arab MD PhD, Belaid Bouhemad MD PhD, NOVACC study group, Maxime Nguyen, Bastien Durand, Audrey Martin, Vivien Berthoud, Tiberiu Constandache, Sandrine Grosjean, Mohamed Radhouani, Jean-Baptiste Anciaux, Pierre Voizeux, Anouck
Cardiac surgery-associated acute kidney injury (CS-AKI) affects up to 30% of patients, increasing morbidity and healthcare costs. This condition results from complex factors like ischemia-reperfusion injury and renal hemodynamic changes, often exacerbated by surgical procedures. Norepinephrine, commonly used in cardiac surgeries, may heighten the risk of CS-AKI. In contrast, vasopressin, a noncatecholaminergic
-
Hemodynamic, ventilatory and gas exchange responses to exercise using a cycle ergometer and the incremental shuttle walk test in pregnant women Am. Heart J. (IF 4.8) Pub Date : 2024-03-15 Alicia Therese Dennis PhD, Emily Traer MB ChB, Hilmy Ismail MD, Bernhard Riedel PhD
Cardiovascular disease, including hypertension, in pregnant women is a leading cause of morbidity and mortality globally. The development of reference intervals for cardiovascular responses using exercising testing to measure oxygen utilisation (V̇O) with cardiopulmonary exercise testing (CPET), and distances walked using the incremental shuttle walk test (ISWT), may be promising methods to assess
-
Predicting the risk of 1-year mortality among patients hospitalized for acute heart failure in China Am. Heart J. (IF 4.8) Pub Date : 2024-03-13 Lihua Zhang MD PhD, Wei Wang PhD, Xiqian Huo MD PhD, Guangda He MD PhD, Yanchen Liu MPH, Yan Li MD, Lubi Lei BM, Jingkuo Li BM, Boxuan Pu BM, Yue Peng BM, Jing Li MD PhD
We aimed to develop and validate a model to predict 1-year mortality risk among patients hospitalized for acute heart failure (AHF), build a risk score and interpret its application in clinical decision making. By using data from China Patient-Centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study, which prospectively enrolled patients hospitalized for AHF in 52 hospitals across
-
Vascular health years after a hypertensive disorder of pregnancy: The EPOCH study Am. Heart J. (IF 4.8) Pub Date : 2024-03-12 Hayley E. Miller MD, Seda Tierney MD, Marcia L. Stefanick PhD, Jonathan A. Mayo MPH, Oshra Sedan PhD, Lisa G. Rosas MPH PhD, Mads Melbye MD DrMed, Heather A. Boyd PhD, David K. Stevenson MD, Gary M. Shaw DrPH, Virginia D. Winn MD PhD, Mark A. Hlatky MD
Preeclampsia is associated with a two-fold increase in a woman's lifetime risk of developing atherosclerotic cardiovascular disease (ASCVD), but the reasons for this association are uncertain. The objective of this study was to examine the associations between vascular health and a hypertensive disorder of pregnancy among women ≥ 2 years postpartum. Pre-menopausal women with a history of either a hypertensive
-
Healthcare utilization and left ventricular ejection fraction distribution in methamphetamine use associated heart failure hospitalizations Am. Heart J. (IF 4.8) Pub Date : 2024-03-11 Veena Manja MBBS MSc PhD, Alexander Tarlochan Singh Sandhu MD, Steven Asch MD, Susan Frayne MD, Mark McGovern PhD, Cheng Chen MS, Paul Heidenreich MD
Although methamphetamine use associated heart failure (MU-HF) is increasing, data on its clinical course are limited due to a preponderance of single center studies and significant heterogeneity in the definition of MU-HF in the published literature. Our objective was to evaluate left ventricular ejection fraction (LVEF) distribution, methamphetamine use treatment engagement and postdischarge healthcare
-
Rationale and design of NUDGE-FLU-CHRONIC and NUDGE-FLU-2: Two nationwide randomized trials of electronic nudges to increase influenza vaccination among patients with chronic diseases and older adults during the 2023/2024 influenza season Am. Heart J. (IF 4.8) Pub Date : 2024-03-07 Niklas Dyrby Johansen MD, Muthiah Vaduganathan MD MPH, Ankeet S. Bhatt MD MBA ScM, Daniel Modin MD, Safia Chatur MD, Brian L. Claggett PhD, Kira Hyldekær Janstrup PhD, Carsten Schade Larsen MD DMSc, Lykke Larsen MD PhD, Lothar Wiese MD PhD, Michael Dalager-Pedersen MD PhD, Lars Køber MD DMSc, Scott D. Solomon MD, Pradeesh Sivapalan MD PhD, Jens Ulrik Stæhr Jensen MD PhD, Cyril Jean-Marie Martel PhD
Yearly influenza vaccination is strongly recommended for older adults and patients with chronic diseases including cardiovascular disease (CVD); however, vaccination rates remain suboptimal, particularly among younger patients. Electronic letters incorporating behavioral nudges are highly scalable public health interventions which can potentially increase vaccination, but further research is needed
-
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial Am. Heart J. (IF 4.8) Pub Date : 2024-03-06 Mitchell Krucoff MD, Alessandro Spirito MD, Usman Baber MD MS, Samantha Sartori PhD, Dominick J. Angiolillo MD PhD, Carlo Briguori MD PhD, David J. Cohen MD MSc, Timothy Collier MSc, George Dangas MD PhD, Dariusz Dudek MD PhD, Javier Escaned MD PhD, C. Michael Gibson MD MSc, Ya-Ling Han MD PhD, Kurt Huber MD, Adnan Kastrati MD, Upendra Kaul MD, Ran Kornowski MD, Vijay Kunadian MBBS MD, Birgit Vogel
The optimal antiplatelet regimen after percutaneous coronary intervention (PCI) in patients with peripheral artery disease (PAD) is still debated. This analysis aimed to compare the effect of ticagrelor monotherapy versus ticagrelor plus aspirin in patients with PAD undergoing PCI. In the TWILIGHT trial, patients at high ischemic or bleeding risk that underwent PCI were randomized after 3 months of
-
Risk calculator for incident atrial fibrillation across a range of prediction horizons Am. Heart J. (IF 4.8) Pub Date : 2024-03-06 Jianhua Wu PhD, Ramesh Nadarajah PhD, Yoko M. Nakao MD, Kazuhiro Nakao MD, Ronen Arbel PhD, Moti Haim MD, Doron Zahger MD, Gregory Y. H. Lip MD, J Campbell Cowan DPhil, Chris P. Gale PhD
-
The protocol of enhanced recovery after cardiac surgery in adult patients: A stepped wedge cluster randomized trial Am. Heart J. (IF 4.8) Pub Date : 2024-03-02 Dou Dou MD, Su Yuan MD, Yuan Jia MD, Yang Wang PhD, Yinan Li MD, Hongbai Wang MD, Jie Ding MD, Xie Wu MD, Dongyun Bie MM, Qiao Liu MD, Ran An MM, Haoqi Yan MM, Fuxia Yan MD
The enhanced recovery after cardiac surgery is a bundle of measurements from preoperative to postoperative phases to improve patients’ recovery. This study is a multicenter, stepwise design, cluster randomized controlled trial. About 3,600 patients presenting during control and intervention periods are eligible if they are aged from 18 to 80 years old awaiting elective cardiac surgery with cardiopulmonary
-
Hypertension, microvascular obstruction and infarct size in patients with STEMI undergoing PCI: Pooled analysis from 7 cardiac magnetic resonance imaging studies Am. Heart J. (IF 4.8) Pub Date : 2024-03-01 Ghazaleh Mehdipoor MD, Björn Redfors MD PhD, Shmuel Chen MD PhD, Fotios Gkargkoulas MD, Zixuan Zhang MS, Manesh R. Patel MD, Christopher B. Granger MD, E. Magnus Ohman MD, Akiko Maehara MD, Ingo Eitel MD, Ori Ben-Yehuda MD, Suzanne de Waha-Thiele MD, Holger Thiele MD, Gregg W. Stone MD
Mortality after ST-segment elevation myocardial infarction (STEMI) is increased in patients with hypertension. The mechanisms underlying this association are uncertain. We sought to investigate whether patients with STEMI and prior hypertension have greater microvascular obstruction (MVO) and infarct size (IS) compared with those without hypertension. We pooled individual patient data from 7 randomized
-
The design of the PRINCESS 2 trial: A randomized trial to study the impact of ultrafast hypothermia on complete neurologic recovery after out-of-hospital cardiac arrest with initial shockable rhythm Am. Heart J. (IF 4.8) Pub Date : 2024-02-28 Emelie Dillenbeck MD, Jacob Hollenberg MD PhD, Michael Holzer MD PhD, Hans-Jörg Busch MD PhD, Graham Nichol MD PhD, Peter Radsel MD PhD, Jan Belohlavec MD PhD, Ervigio Corral Torres MD PhD, Esteban López-de-Sa MD PhD, Fernando Rosell MD PhD, Giuseppe Ristagno MD PhD, Sune Forsberg MD PhD, Filippo Annoni MD PhD, Leif Svensson MD PhD, Martin Jonsson PhD, Denise Bäckström MD PHD, Mikael Gellerfors MD
Delayed hypothermia, initiated after hospital arrival, several hours after cardiac arrest with 8-10 hours to reach the target temperature, is likely to have limited impact on overall survival. However, the effect of ultrafast hypothermia, i.e., delivered intra-arrest or immediately after return of spontaneous circulation (ROSC), on functional neurologic outcome after out-of-hospital cardiac arrest
-
Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction – a secondary analysis of TOPCAT Am. Heart J. (IF 4.8) Pub Date : 2024-02-25 Barna Szabo MD, Lina Benson, Gianluigi Savarese MD PhD, Camilla Hage RN PhD, Marat Fudim MD, Adam Devore MD, Bertram Pitt MD, Lars H Lund MD PhD
Hospitalization for heart failure (HHF) is associated with poor postdischarge outcomes but the role of time since most recent HHF and potential treatment interactions are unknown. We aimed to assess history of and time since previous HHF, associations with composite of cardiovascular (CV) death and total HHF, first HHF and interactions with randomization to spironolactone, in heart failure with preserved
-
Effect of patient factors, center, and era on Fontan timing: An observational study using the Pediatric Health Information Systems Database Am. Heart J. (IF 4.8) Pub Date : 2024-02-25 Bethan A. Lemley MD MSCE, Oluwatimilehin Okunowo MPH, Steve B. Ampah PhD, Lezhou Wu PhD, Russell T. Shinohara PhD, David J. Goldberg MD, Jack Rychik MD, Andrew C. Glatz MD MSCE, Sandra Amaral MD MHS, Michael L. O'Byrne MD MSCE
There are no consensus guidelines defining optimal timing for the Fontan operation, the last planned surgery in staged palliation for single-ventricle heart disease. Identify patient-level characteristics, center-level variation, and secular trends driving Fontan timing. A retrospective observational study of subjects who underwent Fontan from 2007 to 2021 at centers in the Pediatric Health Information
-
Transfemoral transcatheter aortic valve replacement with VitaFlowTM valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-25 Juan Zhang MD, Xiang-Quan Kong MD, Xiao-Fei Gao MD, Jing Chen MD, Xiang Chen MD, Bo Li MD, Yi-Bing Shao MD, Yan Wang MD, Hong Jiang MD, Jian-Cheng Zhu MD, Jun-Jie Zhang MD, Shao-Liang Chen MD, SEASON-AR investigators
Previous studies primarily demonstrated that transfemoral transcatheter aortic valve replacement (TAVR) with self-expanding valve appeared to be a safe and feasible treatment for patients with pure native aortic regurgitation (AR). However, the routine application of transfemoral TAVR for pure AR patients lacks support from randomized trials. SEASON-AR trial is a prospective, multicenter, randomized
-
Depression screening to improve clinical outcomes in coronary heart disease patients Am. Heart J. (IF 4.8) Pub Date : 2024-02-23 Roy C. Ziegelstein MD, Ian M. Kronish MD MPH, Brett D. Thombs PhD
-
Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-23 Sang-Hyup Lee MD, Seung-Jun Lee MD, Jung Ho Heo MD, Sung Gyun Ahn MD, Joon-Hyoung Doh MD, Sanghoon Shin MD, Jaemin Shim MD, Ae-Young Her MD, Byung Gyu Kim MD, Sang Wook Lim MD, Taek-Geun Kwon MD, Kyoung-Hoon Lee MD, Daehoon Kim MD, Yong-Joon Lee MD, Hee Tae Yu MD, Tae-Hoon Kim MD, Dong-Ho Shin MD, Hui-Nam Pak MD, Jung-Sun Kim MD
Both anticoagulation and antiplatelet therapies are recommended after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF). Although contemporary guidelines recommend discontinuation of antiplatelet therapy 1 year after drug-eluting stent (DES) implantation due to excessive bleeding risk, supporting randomized trials are still lacking. The ADAPT AF-DES trial is a multicenter
-
Supermarket/hypermarket opportunistic screening for atrial fibrillation (SHOPS-AF) using sensors embedded in the handles of supermarket trolleys: A feasibility study Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 Ian D. Jones PhD, Deirdre A. Lane PhD, Robyn R. Lotto PhD, David Oxborough PhD, Lis Neubeck PhD, Peter E. Penson PhD, Emma Johnston Smith MSc, Aimeris Santos MD, Emily E. McGinn MRes, Aderonke Ajiboye MPH, Nicola Town PhD, Gabriela Czanner PhD, Andy Shaw PhD, Hala El-Masri MD, Gregory Y.H. Lip MD
Atrial fibrillation (AF) increases the risk of death, stroke, heart failure, cognitive decline, and healthcare costs but is often asymptomatic and undiagnosed. There is currently no national screening program for AF. The advent of validated hand-held devices allows AF to be detected in non-healthcare settings, enabling screening to be undertaken within the community. In this novel observational study
-
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 Vishal N. Rao MD MPH, Abhinav Sharma MD PhD, Amanda Stebbins MSc, John B. Buse MD PhD, Brian G. Katona PharmD, Neha J. Pagidipati MD MPH, Rury R. Holman MB ChB, Adrian Hernandez MD, Robert J. Mentz MD, Renato D. Lopes MD PhD
Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individuals with T2D at risk for cardiovascular disease (CVD). The international EXSCEL trial included 14,752 participants with T2D (73% with established CVD).
-
Angiographic characteristics of patients with STEMI and COVID-19: Insights from NACMI registry Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 Payam Dehghani MD, Jyotpal Singh PhD, G.B. John Mancini MD, Larissa Stanberry PhD, Seth Bergstedt MS, Mina Madan MD MHS, Catherine P. Benziger MD MPH, Nima Ghasemzadeh MD, Anna Bortnick MD PhD, Rohan Kankaria MD, Cindy L. Grines MD, Keshav Nayak MD, Mehmet Yildiz MD, M Chadi Alraies MD MPH, Akshay Bagai MD MHS, Rajan A.G. Patel MD, Shy Amlani MD, Brian C. Case MD, Ron Waksman MD, Jay S. Shavadia MBChB
-
Strategy to optimize PeriproCeduraL AnticOagulation in structural transseptal interventions: Design and rationale of the STOP CLOT trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 Jerzy Pręgowski M.D., Radosław Pracoń M.D., Aleksandra Mioduszewska M.D., Jarosław Skowroński M.D., Lars Sondergaard M.D., Gary S. Mintz M.D., Davide Capodanno M.D., Sang-Wook Kim M.D., Ole De Baker M.D., Piotr Waciński M.D., Wojciech Wojakowski M.D., Adam Rdzanek M.D., Marek Grygier M.D., Michał Chmielecki M.D., Luis Nombela Franco M.D., Patrycjusz Stokłosa M.D., Bohdan Firek M.D., Magdalena Marczak
Both transcatheter edge-to-edge repair (TEER) of mitral regurgitation or left atrial appendage closure (LAAC) require periprocedural anticoagulation with unfractionated heparin (UFH) that is administered either before or immediately after transseptal puncture (TSP). The optimal timing of UFH administration (before or after TSP) is unknown. The Strategy To Optimize PeriproCeduraL AnticOagulation in
-
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 James L. Januzzi Jr. MD, Yuxi Liu MS, Naveed Sattar MD PhD, Yshai Yavin MBChB, Carol A. Pollock MD, Javed Butler MD MPH MBA, Meg Jardine MBBS PhD, Hiddo J.L. Heerspink PhD PharmD, Serge Masson PhD, Matthew Breyer MD, Michael K. Hansen PhD
Circulating concentrations of vascular endothelial growth factor (VEGF) family members may be abnormally elevated in type 2 diabetes (T2D). The roles of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), and VEGF-A in cardio-renal complications of T2D are not established. The 2602 individuals with diabetic kidney disease (DKD) from the Canagliflozin and Renal Events in Diabetes
-
LANDMARK trial: Update in study protocol Am. Heart J. (IF 4.8) Pub Date : 2024-02-16 Akihiro Tobe MD, Yoshinobu Onuma MD PhD, Osama Soliman MD PhD, Andreas Baumbach MD, Patrick W. Serruys MD PhD
-
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program Am. Heart J. (IF 4.8) Pub Date : 2024-02-15 Camilla Fuchs Andersen MD, Julie Hempel Larsen MD, Jesper Jensen MD, Massar Omar MD, Nina Nouhravesh MD, Caroline Kistorp MD PhD, Christian Tuxen MD PhD, Finn Gustafsson MD DMSc, Filip K. Knop MD PhD, Julie Lyng Forman MSc PhD, Filip Soeskov Davidovski MD, Lars Thorbjørn Jensen MD DMSc, Kurt Højlund MD PhD DMSc, Lars Køber MD PhD, Lisbeth Antonsen MD PhD, Mikael Kjær Poulsen MD PhD, Morten Schou MD
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing
-
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria Am. Heart J. (IF 4.8) Pub Date : 2024-02-15 Hiddo JL Heerspink PhD, Michele Provenzano MD, Priya Vart PhD, Niels Jongs PhD, Ricardo Correa-Rotter MD, Peter Rossing MD, Patrick B. Mark MB ChB PhD, Roberto Pecoits-Filho MD, John JV McMurray MD, Anna Maria Langkilde MD, David C. Wheeler MD, Robert B. Toto MD, Glenn M. Chertow MD
Sodium–glucose cotransporter 2 inhibitors decrease blood pressure in patients with type 2 diabetes, but the consistency and magnitude of blood pressure lowering with dapagliflozin in patients with chronic kidney disease (CKD) is unknown. We conducted a prespecified analysis of the DAPA-CKD trial to investigate the effect of dapagliflozin on systolic blood pressure (SBP) in patients with CKD, with and
-
Door-to-diuretic time and mortality in patients with acute heart failure: A systematic review and meta-analysis Am. Heart J. (IF 4.8) Pub Date : 2024-02-13 Thalys Sampaio Rodrigues MD MEpi, Levindo Jose Garcia Quarto MD, Savio Carvalho Nogueira MD, James D. Theuerle MBBS MSc, Omar Farouque MBBS PhD, Louise M. Burrell MBChB MD, Anoop N. Koshy MBBS PhD
Early decongestion therapy with intravenous diuretics may be associated with improved outcomes in acute heart failure (AHF), however data is conflicting. This meta-analysis sought to evaluate the impact of door-to-IV diuretic (D2D) time on mortality in patients with AHF. Pooled estimates from observational studies comprising 28,124 patients, early IV diuresis (reference time 30-105 minutes) was associated
-
Gamification-augmented home-based exercise for peripheral artery disease: Rationale and design of the GAMEPAD Study Am. Heart J. (IF 4.8) Pub Date : 2024-02-13 Alexander C. Fanaroff MD MHS, Samantha Coratti BA, David Farraday BA, Laurie Norton MA MBE, Charles Rareshide MA, Jingsan Zhu MS MBA, Michael G. Levin MD, Scott M. Damrauer MD, Jay S. Giri MD MHS, Neel P. Chokshi MD MBA, Benjamin M. Jackson MD MS, Mitesh S. Patel MD MBA
Supervised exercise therapy improves walking performance, functional capacity, and quality of life in patients with peripheral artery disease (PAD). However, few patients with PAD are enrolled in supervised exercise programs, and there are a number of logistical and financial barriers to their participation. A home-based walking intervention is likely to be more accessible to patients with PAD, but
-
Should ECG criteria for Low QRS voltage (LQRSV) be specific for Sex? Am. Heart J. (IF 4.8) Pub Date : 2024-02-09 Jason V Tso MD, Samuel Montalvo PhD, Jeffrey Christle PhD, David Hadley PhD, Victor Froelicher MD
Low QRS peak-to-nadir voltage (LQRSV) is associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) and other cardiomyopathies. Recent studies have proposed criteria for LQRSV when screening athletes for cardiovascular disease. These criteria have not yet been evaluated in a large population of healthy young athletes. The target population was 10,728 (42.5% female, 57.5% male, mean age
-
Plasma proteomics for prediction of subclinical coronary artery calcifications in primary prevention Am. Heart J. (IF 4.8) Pub Date : 2024-02-05 Patrick Royer MD, Elias Björnson PhD, Martin Adiels PhD, María Bueno Álvez PhD, Linn Fagerberg PhD, Fredrik Bäckhed PhD, Mathias Uhlén PhD, Anders Gummesson MD PhD, Göran Bergström MD PhD
Recent developments in high-throughput proteomic technologies enable the discovery of novel biomarkers of coronary atherosclerosis. The aims of this study were to test if plasma protein subsets could detect coronary artery calcifications (CAC) in asymptomatic individuals and if they add predictive value beyond traditional risk factors. Using proximity extension assays, 1,342 plasma proteins were measured
-
TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Elvin Kedhi MD PhD, Andi Rroku MD, Rik S. Hermanides MD PhD, Jan Henk Dambrink MD PhD, Sandeep Singh MD, Jurriën Ten Berg MD, Dirk-Jan van Ginkel MD, Martin Hudec MD PhD, Giovanni Amoroso MD PhD, Ignacio J. Amat-Santos MD PhD, Martin Andreas MD PhD, Rui Campante Teles MD PhD, Guillaume Bonnet MD PhD, Eric Van Belle MD PhD, Lenard Conradi MD PhD, Leen van Garsse MD PhD, Wojtek Wojakowski MD PhD, Vasileious
Patients with severe aortic stenosis (AS) frequently present with concomitant obstructive coronary artery disease (CAD). In those, current guidelines recommend combined coronary artery bypass grafting (CABG) and surgical aortic valve replacement (SAVR) as the preferred treatment option, although this surgical approach is associated with a high rate of clinical events. Combined transcatheter aortic
-
Regional differences in outcomes with ablation versus drug therapy for atrial fibrillation: Results from the CABANA trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Riccardo Cappato MD, Daniel B. Mark MD MPH, Adam P. Silverstein MS, Peter A. Noseworthy MD, Gianluca Bonitta PhD, Jeanne E. Poole MD, Jonathan P. Piccini MD, Tristram D. Bahnson MD, Melanie R. Daniels BA, Hussein R. Al-Khalidi PhD, Kerry L. Lee PhD, Douglas L. Packer MD, CABANA Investigators
The finding of unexpected variations in treatment benefits by geographic region in international clinical trials raises complex questions about the interpretation and generalizability of trial findings. We observed such geographical variations in outcome and in the effectiveness of atrial fibrillation (AF) ablation versus drug therapy in the Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial
-
Variability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Kim G. Smolderen PhD, Gaëlle Romain PhD, Jacob Cleman MD, Lindsey Scierka MD, Carlos Mena-Hurtado MD
The use of guideline-directed medical therapy (GDMT) in patients undergoing peripheral vascular interventions (PVIs) decreases the risk of death and amputation and may decrease hospital readmissions. The variability of GDMT prescription across sites and operators and the proportionality of risk is not well understood. We aimed to study the association between variability of GDMT prescription at the
-
Intracoronary electrocardiogram detects coronary microvascular dysfunction and ischemia in patients with no obstructive coronary arteries disease Am. Heart J. (IF 4.8) Pub Date : 2024-01-25 Erdem Cevik MD, Ahmet Tas MD, Zeynep G. Demirtakan MD, Peter Damman MD PhD, Yaren Alan BSc, Christopher J. Broyd MD PhD, Alp Ozcan MD, Duygu H. Simsek MD, Mehmet R. Sonsoz MD, Niels van Royen MD, Divaka Perera MD, Justin E. Davies MD PhD, Sabahattin Umman MD, Murat Sezer MD
-
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings Am. Heart J. (IF 4.8) Pub Date : 2024-01-22 James E Ip MD, Hanh Bui MD MPH, A John Camm MD, Benoit Coutu MD, Peter A. Noseworthy MD MBA, Maria Leonor Parody MD, Samuel F Sears PhD, Narendra Singh MD, Juan Agudelo Uribe MD, John Vyselaar MD, Sarah Omodele DNP, Silvia Shardonofsky MD MSc, David B. Bharucha MD PhD, Bruce Stambler MD
Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute episodes of PSVT in the clinical setting consists of intravenous adenosine, beta-blockers, and calcium channel blockers (CCBs). Etripamil is an intranasally self-administered
-
Radial artery vs right internal mammary artery as a second conduit during coronary artery bypass grafting Am. Heart J. (IF 4.8) Pub Date : 2024-01-20 Eishan Ashwat BS, James A. Brown MD MS, Sarah Yousef MD MS, Danial Ahmad MD, Yisi Wang MPH, Floyd W. Thoma BS, Derek Serna-Gallegos MD, Pyongsoo Yoon MD, David West MD, Danny Chu MD, Johannes Bonatti MD, David Kaczorowski MD, Ibrahim Sultan MD
To compare the clinical outcomes of radial artery (RA) grafts during CABG to those of right internal mammary artery (RIMA) grafts. This was a retrospective, single-institution cohort study of isolated CABG with multiple grafts between 2010-2022. To balance graft cohorts, propensity score matching (PSM) was performed using a 1:1 match ratio. Long-term postoperative survival was compared among RA and
-
Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial Am. Heart J. (IF 4.8) Pub Date : 2024-01-20 Nidal Jammoul MD, Valentin Dupasquier MD, Mariama Akodad MD PhD, Pierre-Alain Meunier MD, Lionel Moulis MD, Sonia Soltani, Jean-Christophe Macia MD, Pierre Robert MD, Laurent Schmutz MD, Matthieu Steinecker MD, Christophe Piot MD, Frederic Targosz MD, Henri Benkemoun MD, Benoît Lattuca MD PhD, François Roubille MD PhD, Guillaume Cayla MD PhD, Florence Leclercq MD PhD
Safety and feasibility of transcatheter aortic valve replacement (TAVR) without balloon aortic valvuloplasty (BAV) using the SAPIEN 3 balloon-expandable device has been previously demonstrated. The impact on long-term valve hemodynamic performances and outcomes remains however unknown. We evaluate long-term clinical and hemodynamic results according to the implant strategy (direct TAVR vs BAV pre-TAVR)
-
Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank Am. Heart J. (IF 4.8) Pub Date : 2024-01-17 Konstantin A. Krychtiuk, Tomas LG Andersson, Ulrike Bodesheim, Javed Butler, Lesley H. Curtis, Mitchell Elkind, Adrian F. Hernandez, Christoph Hornik, Gary H. Lyman, Pooja Khatri, Michael Mbagwu, Masahiro Murakami, Gwen Nichols, Lothar Roessig, Anne Quinn Young, Richard L. Schilsky, Neha Pagidipati
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a large part of mortality and disability worldwide is stalled. To examine the processes of novel drug development for common chronic health conditions
-
Identifying the highest risk vascular patients: Insights from the XATOA registry Am. Heart J. (IF 4.8) Pub Date : 2024-01-12 Sonia S. Anand MD PhD FRCPc FRSC, Victor Aboyans MD PhD FAHA FESC FJCS, Jackie Bosch PhD MSc BSc OT(Reg), Sebastian Debus MD FEBS FEBVS, Alain Gay MD, Manesh R. Patel MD, Kai Vogtländer M.Sc., Robert C. Welsh MD FRCPC, Uwe Zeymer MD, Keith A.A. Fox BSc (hons) MB ChB FRCP F Med Sci, XATOA Steering Committee
Patients with coronary and peripheral artery disease (PAD) have a residual risk of major adverse cardiovascular and limb events despite standards of care. Among patients with coronary artery disease (CAD) and/or PAD selected for low dose rivaroxaban (2.5 mg BID) and aspirin, we sought to determine the highest risk vascular patients. Xarelto pluc Acetylsalicylic acid: Treatment patterns and Outcomes
-
Enhancing Lifestyles in the Metabolic syndrome (ELM) multisite behavioral efficacy trial. Design and baseline cohort Am. Heart J. (IF 4.8) Pub Date : 2024-01-10 ELM Trial Research Group, Lynda H. Powell PhD, Bryce T. Daniels PhD, Betty M. Drees MD, Kelly Karavolos MA, Barbara Lohse PhD RDN, Kevin S Masters PhD, Jacinda M Nicklas MD MPH, Elizabeth H. Ruder PhD, Sumihiro Suzuki PhD, Nicole Trabold PhD, Laura J. Zimmermann MD
-
Trial outcome definitions require more attention Am. Heart J. (IF 4.8) Pub Date : 2024-01-08 David Füller MBBS
Abstract not available
-
Prognostic performance of the IABP-SHOCK II Risk Score among cardiogenic shock subtypes in the critical care cardiology trials network registry Am. Heart J. (IF 4.8) Pub Date : 2024-01-06 Carlos L. Alviar MD, Boyangzi K. Li MD PhD, Norma M. Keller MD, Erin Bohula-May MD DPhil, Christopher Barnett MD MPH, David D. Berg MD MPH, James A. Burke MD, Sunit-Preet Chaudhry MD, Lori B. Daniels MD MAS, Andrew P. DeFilippis MD, Daniel Gerber MD, James Horowitz MD, Jacob C. Jentzer MD, Praneeth Katrapati MD, Ellen Keeley MD, Patrick R. Lawler MD MPH, Jeong-Gun Park PhD, Shashank S. Sinha MD MSc
Risk stratification has potential to guide triage and decision-making in cardiogenic shock (CS). We assessed the prognostic performance of the IABP-SHOCK II score, derived in Europe for acute myocardial infarct-related CS (AMI-CS), in a contemporary North American cohort, including different CS phenotypes. The critical care cardiology trials network (CCCTN) coordinated by the TIMI study group is a
-
Burden of cardiometabolic risk factors and vascular health Am. Heart J. (IF 4.8) Pub Date : 2024-01-05 Carine E. Hamo MD MHS, Florencia Schlamp PhD, Kamelia Drenkova, Manila Jindal MD, Maja Fadzan, Adedoyin Akinlonu MD MPH, Ira Goldberg MD, Michael S. Garshick MD, Jeffrey S. Berger MD
Cardiometabolic risk factors diabetes, obesity, and hypertension are highly prevalent and contribute to increased cardiovascular disease (CVD). Endothelial dysfunction precedes CVD development. The current study aimed to investigate the EC transcriptome among individuals with varying degree of cardiometabolic risk. Adult participants without CVD and various degrees of cardiometabolic risk factor burden
-
Preoperative computed tomography-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-30 Romy R.M.J.J. Hegeman MD, Dirk-Jan van Ginkel MD, Severin Laengle MD, Leo Timmers MD PhD, Benno J.W.M. Rensing MD PhD, Thomas L. de Kroon MD, Uday Sonker MD, Johannes C. Kelder MD PhD, Markus Mach MD PhD, Martin Andreas MD PhD, Martin J. Swaans MD PhD, Jurriën M. ten Berg MD PhD, Patrick Klein MD PhD
Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic valve stenosis, but is still associated with relatively high rates of pacemaker implantation and paravalvular regurgitation. Routine preoperative computed tomography (CT) combined with patient-specific computer modelling can predict the interaction between the TAVI device and the patient's
-
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-29 Erin A. Bohula MD DPhil, Nicholas A. Marston MD MPH, Andrea Ruzza MD PhD, Sabina A. Murphy MPH, Gaetano M. De Ferrari MD, Rafael Diaz MD, Lawrence A. Leiter MD, Mary Elliott-Davey MSc, Huei Wang PhD, Ajay K. Bhatia MD PhD, Robert P. Giugliano MD SM, Marc S. Sabatine MD MPH
-
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI Am. Heart J. (IF 4.8) Pub Date : 2023-12-26 Arsalan Abu-Much MD, Cindy L. Grines MD, Wayne B. Batchelor MD, Aneel S. Maini MD, Yiran Zhang MS, Björn Redfors MD PhD, Lavanya Bellumkonda MD, Aditya S. Bharadwaj MD, Jeffrey W. Moses MD, Alexander G. Truesdell MD, Yanru Li MS MPH, Suzanne J. Baron MD MSc, Alexandra J. Lansky MD, Mir B. Basir DO, David J. Cohen MD MSc, William W. O'Neill MD
-
Overview of the 2023 FDA Circulatory System Devices Advisory Panel Meeting on the Symplicity Spyral Renal Denervation System Am. Heart J. (IF 4.8) Pub Date : 2023-12-20 Kalyan R. Chitturi DO, Dan Haberman MD, Jason P. Wermers MS, Ron Waksman MD
Hypertension remains a leading preventable cause of myocardial infarction, stroke, kidney disease, and cardiovascular death worldwide. Despite lifestyle modifications and intensification of medical therapy, suboptimal blood pressure control is common, spurring the development of device-based therapies for hypertension. The US Food and Drug Administration (FDA) assembled the Circulatory System Devices
-
Effects of trimetazidine on cardiac function in adult cyanotic congenital heart disease patients: Protocol for a 3-month multicenter, randomized, double-blind controlled trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-20 Yi Shen MD PhD, Li Xiang MD PhD, Yifan Zhu MD PhD, Chenyu Jiang MD PhD, Xingliang Zhou MD PhD, Xu Huang MD, Liwei Wu MD PhD, Bei Feng PhD, Yi Yan MD PhD, Yiwei Liu MD PhD, Hao Zhang MD PhD
Nearly 20% Patients with cyanotic congenital heart disease (CCHD) are not able to receive surgery. These patients experience a decline in cardiac function as they age, which has been demonstrated to be associated with changes in energy metabolism in cardiomyocytes. Trimetazidine (TMZ), a metabolic regulator, is supposed to alleviate such maladaptation and reserve cardiac function in CCHD patients.
-
Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-18 Mijin Kim MD, Jung-Min Ahn MD, Do-Yoon Kang MD, Min-Ju Kim PhD, Kyung Won Kim MD, Hyun Jung Koo MD, Dong Hyun Yang MD, Seung Chai Jung MD, Byungjun Kim MD, Yiu Tung Anthony Wong MD, Cheung Chi Simon Lam MD, Wei‐Hsian Yin MD, Jeng Wei MD, Yung-Tsai Lee MD, Hsien-Li Kao MD, Mao-Shin Lin MD, Tsung Yu Ko MD, Won-Jang Kim MD, Se Hun Kang MD, Seung-Ah Lee MD, Euihong Ko MD, Dae-Hee Kim MD, Joon-Won Kang
-
Feasibility of double-blinded, placebo-controlled interventional study for assessing catheter ablation efficacy in persistent atrial fibrillation: Insights from the ORBITA AF feasibility study Am. Heart J. (IF 4.8) Pub Date : 2023-12-17 Vijayabharathy Kanthasamy MBBS MRCP, Richard Schilling MD FRCP, Olivier Zongo, Kamran Khan, Mark Earley MD FRCP, Vivienne Monk PhD, Ross Hunter PhD FRCP, Valentina Mangiafico MBBS, Richard Ang PhD FRCP, Antonio Creta PhD, Nikhil Aluwhalia MBBS MRCP, Shohreh Honarbakhsh PhD, Mehul Dhinoja MD, Dhiraj Gupta MD FRCP, Malcolm Finlay PhD FRCP
-
The prognostic significance of single-lead ST-segment resolution in ST-segment elevation myocardial infarction patients treated with primary PCI – A substudy of the randomized TOTAL trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Marko Sirén MD, Joonas Leivo MD, Eero Anttonen MD, Sanjit S. Jolly MD, Vladimir Dzavik MD, Jyri Koivumäki MD, Minna Tahvanainen MD, Kimmo Koivula MD, Jia Wang MSc, John A. Cairns MD, Kari Niemelä MD, Markku Eskola MD, Kjell C. Nikus MD, Jussi Hernesniemi MD
ST-segment elevation myocardial infarction (STEMI) is associated with high morbidity and mortality worldwide. Simple electrocardiogram (ECG) tools, including ST-segment resolution (STR) have been developed to identify high-risk STEMI patients after primary percutaneous coronary intervention (PCI). We evaluated the prognostic impact of STR in the ECG lead with maximal baseline ST-segment elevation (STE)
-
Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Faizan Mazhar, Paul Hjemdahl, Arvid Sjölander, Thomas Kahan, Tomas Jernberg, Juan Jesus Carrero
The effectiveness of lipid-lowering therapy (LLT) for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in routine care may depend on treatment intensity and adherence. Observational study of adults with newly initiated LLT for primary prevention of ASCVD in Stockholm, Sweden, during 2017-2021. Study exposures were LLT adherence [proportion of days covered (PDC)], LLT intensity (expected
-
Sex-specific heart failure burden across the United States: Global burden of disease 1990-2019 Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Pedro RVO Salerno MD, Zhuo Chen PhD, Sojin Wass MD, Issam Motairek MD, Chantal Elamm MD, Lúcia MVO Salerno MD, Neda Shafiabadi Hassani MD, Salil V. Deo MD, Sadeer G Al-Kindi MD
-
Study design and rationale of COMPETE: Comparison of the effect of medication therapy in alleviating migraine with patent foramen ovale Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Ziping Li, Jie Dong, Yiming Yan, Fang Fang, Chuangshi Wang, Fengwen Zhang, Wenbin Ouyang, Shouzheng Wang, Xiangbin Pan
Previous studies have examined the impact of antithrombotic agents on Patent Foramen Ovale (PFO) in relation to migraine. However, differences in effectiveness of different antithrombotic agents and traditional migraine medications are not known. This study is an investigator-initiated, randomized, multicenter, single-masked (outcomes assessor), and active-controlled parallel-group trial (ClinicalTrials
-
Study of heart function in PRE-Eclampsia during and after PreGnancy (SHePREG): The pilot cohort Am. Heart J. (IF 4.8) Pub Date : 2023-12-14 Marwan Ma'ayeh MD, Omer Cavus MD, Lauren J. Hassen MD, Martin Johnson MD PhD, Taryn Summerfield MS, Mosammat Begom MS, Amanda Cai MD, Laxmi Mehta MD, Kara Rood MD, Elisa A. Bradley MD
-
Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters Am. Heart J. (IF 4.8) Pub Date : 2023-12-12 Sarah C. Montembeau BA, Birju R. Rao MD, Andrea R. Mitchell MPH, Candace D. Speight MPH, Larry A. Allen MD MHS, Scott D. Halpern MD PhD, Yi-An Ko PhD, Daniel D. Matlock MD MPH, Miranda A. Moore PhD, Alanna A. Morris MD MSc, Laura D. Scherer PhD, Peter Ubel MD, Neal W. Dickert MD PhD
-
Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries Am. Heart J. (IF 4.8) Pub Date : 2023-12-10 Matthew R. Reynolds MD MSc, Rod Passman MD, Jason Swindle PhD, Iman Mohammadi PhD, Brent Wright RN DrPHc, Kenneth Boyle DC, Mintu P. Turakhia MD MS, Suneet Mittal MD
Objective data comparing the diagnostic performance of different ambulatory cardiac monitors (ACMs) are lacking. To assess variation in monitoring strategy, clinical outcomes and healthcare utilization in patients undergoing ambulatory monitoring without a pre-existing arrhythmia diagnosis. Using the full sample (100%) of Medicare claims data, we performed a retrospective cohort study of diagnostic-naïve
-
NatIonal Danish endocarditis stUdieS – Design and objectives of the NIDUS registry Am. Heart J. (IF 4.8) Pub Date : 2023-12-04 Peter L. Graversen, Katra Hadji-Turdeghal, Jacob Eifer Møller, Niels Eske Bruun, Hicham Laghmoch, Andreas Dalsgaard Jensen, Jeppe K. Petersen, Henning Bundgaard, Kasper Iversen, Jonas A Povlsen, Claus Moser, Morten Smerup, Hanne Sortsøe Jensen, Peter Søgaard, Jannik Helweg-Larsen, Daniel Faurholt-Jepsen, Lauge Østergaard, Lars Køber, Emil L. Fosbøl
Aims The National Danish endocarditis stUdieS (NIDUS) registry aims to investigate the mechanisms contributing to the increasing incidence of IE and to discover risk factors associated to the course, treatment and clinical outcomes of the disease. Methods The NIDUS registry was created to investigate a nationwide unselected group of patients hospitalized for infective endocarditis (IE). The National
-
Design and Rationale of the Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: The EARLY TAVR Trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-04 Philippe Généreux, Allan Schwartz, Brad Oldemeyer, David J. Cohen, Björn Redfors, Heather Prince, Yanglu Zhao, Brian R. Lindman, Philippe Pibarot, Martin B. Leon
Background For patients with asymptomatic, severe aortic stenosis (AS) and preserved left ventricular ejection fraction, current guidelines recommend clinical surveillance every 6 to 12 months. To date, no randomized trials have examined whether an early intervention with transcatheter aortic valve replacement (TAVR) will improve outcomes among these patients. Study Design and Objectives EARLY TAVR